The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has given its nod to topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis. The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. in seborrheic dermatitis. This a a chronic disease,” he says. “We

Dermatitis 36

Dermatitis Safety Clinic Medical 36

The Dermatology Digest

FEBRUARY 8, 2024

It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

Art of Dermatology

AUGUST 28, 2023

Alcohol is now proven to shorten our telomeres , the “safety tips” on the ends of our DNA strands that keep them from unraveling and which keep our cells young and behaving properly. Seborrheic Dermatitis Seborrheic dermatitis is a common skin condition associated with inflamed, greasy, flaky patches on the skin.

Rosacea 36

Rosacea Dermatitis Skincare Routine Hydration 36

The Dermatology Digest

AUGUST 4, 2023

They extrapolated that across 15 million office visits. Biologic Prescribing Challenges Not every psoriasis, eczema, or atopic dermatitis patient gets 100% response from biologics, said Dr. So, ask the patient what they want, give them their options and let them make an educated choice.” It has a great [safety and efficacy] profile.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis.

Safety 74

Safety Office Dermatitis Clinic 74

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The primary endpoint of the clinical trial was safety and tolerability. Brady, MD, PhD, President and Chief Executive Officer of Aldeyra.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. In addition, due to its unique function on peripheral sensory neurons, EVO756 could provide fast relief of itch associated with inflammatory diseases, such as atopic dermatitis.

Safety 36

Safety Office Dermatitis Clinic 36

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36

Aesthetics Advisor

JUNE 16, 2024

But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.” Says Dr. Hartman, the lack of safety data and FDA approval are what make exosomes in serums and creams such a contentious trend. freeze) them. Hartman refers to exosomes as "the AI of skin care."

Aromatherapy 36

Aromatherapy Injections Ingredients Moisturization 36